Reckitt Benckiser Group Plc (LON:RB) has received a consensus rating of “Hold” from the twenty-one ratings firms that are presently covering the company, MarketBeat.com reports. Three investment analysts have rated the stock with a sell rating, eight have issued a hold rating and ten have assigned a buy rating to the company. The average 12 month target price among analysts that have covered the stock in the last year is GBX 6,884.71 ($89.96).
RB has been the topic of several recent research reports. Citigroup reissued a “buy” rating and set a GBX 7,650 ($99.96) price objective (up previously from GBX 7,200 ($94.08)) on shares of Reckitt Benckiser Group in a report on Thursday, August 30th. JPMorgan Chase & Co. lifted their price objective on Reckitt Benckiser Group from GBX 7,000 ($91.47) to GBX 9,000 ($117.60) and gave the stock an “overweight” rating in a report on Thursday, September 6th. Morgan Stanley lifted their price objective on Reckitt Benckiser Group from GBX 8,500 ($111.07) to GBX 8,800 ($114.99) and gave the stock an “overweight” rating in a report on Tuesday, October 2nd. Credit Suisse Group set a GBX 5,850 ($76.44) price objective on Reckitt Benckiser Group and gave the stock a “sell” rating in a report on Wednesday, September 19th. Finally, UBS Group lifted their price objective on Reckitt Benckiser Group from GBX 6,000 ($78.40) to GBX 6,400 ($83.63) and gave the stock a “neutral” rating in a report on Monday, September 17th.
RB opened at GBX 6,647 ($86.85) on Friday. Reckitt Benckiser Group has a 12-month low of GBX 5,562 ($72.68) and a 12-month high of GBX 8,110.43 ($105.98).
Reckitt Benckiser Group plc manufactures, markets, and sells health, hygiene, and home products. The company offers products for the treatment of analgesic and gastro-intestinal problems, sore throat, cough, pain, and flu, as well as wellness products in sexual wellbeing, footcare, vitamins, and supplements under the Durex, Gaviscon, Nurofen, Mucinex, Scholl/Amopé, and Strepsils brand names.
Featured Article: Fundamental Analysis and Individual Investors
Receive News & Ratings for Reckitt Benckiser Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reckitt Benckiser Group and related companies with MarketBeat.com's FREE daily email newsletter.